Article Text

Download PDFPDF
Efficacy and safety of pallidal stimulation in primary dystonia: results of the Spanish multicentric study
  1. F Valldeoriola1,
  2. I Regidor2,
  3. A Mínguez-Castellanos3,
  4. E Lezcano4,
  5. P García-Ruiz5,
  6. A Rojo6,
  7. A Salvador7,
  8. A Castro8,
  9. F Grandas9,
  10. J Kulisevsky10,
  11. M J Martí1,
  12. P Martínez-Martín11,
  13. L Relova8,
  14. J Rumià1,
  15. A Cámara1,
  16. J A Burguera12,
  17. G Linazasoro13,
  18. J López de Val14,
  19. J Obeso15,
  20. M C Rodríguez-Oroz15,
  21. E Tolosa1
  1. 1
    Hospital Clínic, University of Barcelona, Barcelona, Spain
  2. 2
    Hospital Ramón y Cajal, Madrid, Spain
  3. 3
    Hospital Universitario Virgen de las Nieves, Granada, Spain
  4. 4
    Hospital de Cruces, Baracaldo, Spain
  5. 5
    Fundación Jiménez-Díaz, Madrid, Spain
  6. 6
    Hospital Mútua de Terrassa, Spain
  7. 7
    Hospital Clínic, València, Spain
  8. 8
    Hospital Universitario, Santiago de Compostela, Spain
  9. 9
    Hospital Gregorio Marañón, Madrid, Spain
  10. 10
    Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  11. 11
    Instituto Nacional de Epidemiología, CIBERNED, Instituto de Salud Carlos III, Madrid, Spain
  12. 12
    Hospital La Fe, Valencia, Spain
  13. 13
    Clínica Donosti, San Sebastián, Spain
  14. 14
    Hospital Clínico, Zaragoza, Spain
  15. 15
    Clínica Universitaria de Navarra, Madrid, Spain
  1. Correspondence to Dr F Valldeoriola, Parkinson’s Disease and Movement Disorders Unit, Institut Clínic de Neurociències, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona 08036, Spain; fvallde{at}clinic.ub.es

Abstract

Background: Dystonia is a complex clinical syndrome originated by a wide range of aetiologies. The diagnosis of dystonia is made after the evaluation of aetiological, phenomenological and genetic factors.1 Medications, except in patients with dopa-responsive dystonia, are of limited efficacy. Botulinum toxin injections are not applicable to patients with generalised dystonia, since many muscular groups contribute to disability.2

Clinical studies in children and adults with primary generalised dystonia (PGD) have reported beneficial effects of bilateral GPi deep brain stimulation (DBS) in both motor symptoms and disability produced by dystonia3 4 5 as well as a favourable impact of DBS in the health-related quality of life (HRQoL).6 Some clinical aspects of GPi stimulation in primary dystonia still remain controversial such as the influence of disease duration or age at onset in determining the postoperative clinical outcome.

Results: The authors report the results of a multicentric study designed to assess the tolerability and clinical effects of bilateral pallidal DBS on motor impairment, functional disability, quality of life, pain and mood in patients with medically refractory primary generalised or segmental dystonia.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Members of “GESPALDIS”: C Magariños, R Figueiras, L Cabañes (H Ramón y Cajal, Madrid); F Escamilla-Sevilla, MJ Katati, JM Martin-Linares (H Universitario Virgen de las Nieves, Granada); G Bilbao, I Lambarri, JC Gómez, O Rodriguez, R Villoria (H de Cruces, Baracaldo); F Alonso, J Ayerbe, J Muñiz (Fundación Jiménez Díaz, Madrid); B Oliver, M Aguilar, D Badenes (H Mútua de Terrassa); P Roldán, F Talamantes (H Clínic, València); A Sésar, M Gelabert (H Clínico Universitario, Santiago de Compostela); L López, S Giménez-Roldán, F Garcia (H Gregorio Marañón, Madrid); A Gironell, J Molet, RB Pascual-Sedano, R Rodríguez (Hospital de la Santa Creu i Sant Pau, Barcelona).

  • Competing interests None.

  • Ethics approval Ethics approval was provided by the Ethics Committee at each institution participating in the study.

  • Patient consent Obtained.

  • Members of “GESPALDIS”: C Magariños, R Figueiras, L Cabañes (H Ramón y Cajal, Madrid); F Escamilla-Sevilla, MJ Katati, JM Martin-Linares (H Universitario Virgen de las Nieves, Granada); G Bilbao, I Lambarri, JC Gómez, O Rodriguez, R Villoria (H de Cruces, Baracaldo); F Alonso, J Ayerbe, J Muñiz (Fundación Jiménez Díaz, Madrid); B Oliver, M Aguilar, D Badenes (H Mútua de Terrassa); P Roldán, F Talamantes (H Clínic, València); A Sésar, M Gelabert (H Clínico Universitario, Santiago de Compostela); L López, S Giménez-Roldán, F Garcia (H Gregorio Marañón, Madrid); A Gironell, J Molet, RB Pascual-Sedano, R Rodríguez (Hospital de la Santa Creu i Sant Pau, Barcelona).

  • Provenance and Peer review Not commissioned; externally peer reviewed.